Astellas Pharma Inc. (AP) has undergone many significant changes and announcements over the past year. AP collaborated with YASKAWA, aiming to boost the cell therapy ecosystem, underlining their commitment to innovation. Michael Petroutsas assumed his role as head of U.S. commercial operations. Despite reporting earnings that missed analysts' forecasts, it's not a major concern as AP is backed by a strong institutional ownership of 59%. AP's scientific advancements were highlighted in the ASCO Annual Meeting. Several partnerships were announced, including Inverna Inc. for therapeutic bispecific antibody research, Poseida Therapeutics for novel therapeutics research, and a collaboration with Mass General Brigham.
Acquisitions included Propella Therapeutics for $175m and Iveric Bio. FDA granted orphan drug and pediatric exclusivities for CRESEMBA
®. Japanese regulatory bodies approved VYLOY
™ for treating gastric cancer. However, not all news was positive; AP faced a setback with FDA denial for their gastric cancer drug and their bid to block Myrbetriq copies during a patent suit was lost. Albeit mixed, AP's activities show their commitment to growth, innovation and the development of diverse novel therapies.
Astellas Pharma Inc. News Analytics from Tue, 13 Jun 2023 02:03:41 GMT to Sat, 01 Jun 2024 06:50:41 GMT -
Rating 4
- Innovation 6
- Information 7
- Rumor 3
